Clinical trials
Kidney Transplantation Recipients clinical trials
Below are recruiting kidney transplantation recipients clinical trials, each written for real people, not researchers. We’re tracking 150 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06126380Enrolling by invitationPhase 2
Long-term safety of tegoprubart in kidney transplant patients
This is a long-term follow-up study for people who have already completed a study of the drug tegoprubart after a kidney transplant. It checks how safe and effective the drug is over a longer period.
Los Angeles, CaliforniaAges 18–100 - NCT05224583Enrolling by invitation
Study BK virus after combined liver and kidney transplant
This study looks at how often BK virus shows up in people after a combined liver-kidney transplant. It may help the transplant team better predict and manage this virus after surgery.
Dallas, TexasAges 18–100 - NCT06759961Recruiting
Outcomes after kidney transplant for a blood vessel condition
This study looks at outcomes after kidney transplant for a rare blood vessel condition called thrombotic microangiopathy. It aims to learn more about how patients do after transplant at a specific center in Bologna, Italy.
Bologna, BOAges 18 years+ - NCT06314230Recruiting
Genomics of chronic kidney transplant failure study
This study looks at how genes affect long-term kidney transplant health. It aims to understand why some transplanted kidneys fail over time, and may help personalize care for transplant recipients.
Westmead, New South WalesAges 18–75 - NCT06833463Recruiting
Tacrolimus and diabetes risk in kidney transplant patients
This study looks at how the anti-rejection drug tacrolimus (specifically Envarsus) affects blood sugar and risk of diabetes in kidney transplant patients. It aims to find out which patients might be more likely to develop glucose problems so doctors can adjust treatment early.
GdanskAges 18 years+ - NCT06100965Recruiting
Lower dose alemtuzumab for kidney transplant rejection
This trial tests a reduced dose of alemtuzumab, a medicine that calms the immune system, for people whose kidney transplant is being rejected and standard treatments haven't worked or aren't safe.
Rotterdam, South HollandAges 18 years+ - NCT04182607Recruiting
Looking at outcomes after kidney donation surgery
This review looks at results for kidney donors and recipients who had kidney transplant surgery done either by hand-assisted or robotic methods. It aims to understand how these surgical approaches affect donor and recipient outcomes.
Dallas, TexasAges 18 years+ - NCT06337942Recruiting
Bladder or kidney-bladder transplant from a deceased donor
This trial offers a first-in-human transplant of a bladder or a kidney combined with a bladder from a deceased donor. It is for people with severe bladder problems or bladder cancer who already need a new bladder or are on immune-suppressing medicines for a prior organ transplant.
Los Angeles, CaliforniaAges 18–70 - NCT06625073RecruitingPhase 4
SGLT2i for heart transplant recipients
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
Palo Alto, CaliforniaAges 18 years+ - NCT07090512Recruiting
Ultrasound to predict kidney risk after transplant
This study uses ultrasound of donor kidneys to predict the risk of kidney problems after transplant. It may help doctors better understand transplant outcomes.
Jinan, ShandongAges 18 years+ - NCT06706492Recruiting
Muscle oxygen and frailty in kidney transplant patients
This study looks at how well muscles use oxygen and how frailty affects kidney transplant recipients, especially those with weak breathing muscles. It may help understand why some patients feel more tired or weak after transplant.
AnkaraAges 18–65 - NCT01644903Recruiting
Checking biomarkers after a liver transplant
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Chicago, IllinoisAges 18 years+ - NCT06829719Recruiting
Using TTV virus to manage immune drugs in kidney transplant
This trial uses a virus called TTV to see if it can help doctors safely adjust immunosuppression drugs in kidney transplant patients. It aims to find a way to lower the risk of rejection while reducing side effects.
Bordeaux (France)Ages 18 years+ - NCT05385432RecruitingPhase 3
Kidney transplant induction therapy for sensitized patients
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
ToursAges 18–79 - NCT06531967Enrolling by invitation
Predicting survival in kidney transplant recipients
This study looks at factors that may help predict how long kidney transplant recipients live. If you are an adult who has received a single kidney transplant (your first one), you may be able to take part.
Phoenix, ArizonaAges 18–100 - NCT06210555Recruiting
MRI Study of Kidney Donors, Recipients, and Healthy People
This study uses advanced MRI scans to look at kidney health in living donors, transplant recipients, and healthy people. It aims to find links between MRI results and kidney function, fibrosis (scarring), and aging.
Aarhus, Central JutlandAges 18–80 - NCT06235892RecruitingPhase 3
Lowering Tacrolimus for Low-Risk Kidney Transplant Patients
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
NantesAges 18 years+ - NCT07024238Enrolling by invitation
Short-chain fatty acid supplement for kidney transplant patients
This study tests whether taking a short-chain fatty acid (a type of fiber-like substance) supplement can improve gut health in people who have had a kidney transplant. It may help keep the transplant working well.
Martin, SlovakiaAges 18 years+ - NCT04877288RecruitingPhase 3
Switch some teen kidney transplant patients to belatacept
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
Birmingham, AlabamaAges 12–17 - NCT07423247RecruitingPhase 4
Tirzepatide for weight loss in kidney transplant patients
This trial tests if tirzepatide can help people who have had a kidney transplant and are still overweight lose weight. It may be an option if you have had your transplant at least a year ago, your kidney function is stable, and your body mass index is 27 or higher.
TehranAges 18 years+ - NCT05702398RecruitingEarly Phase 1
Vitamin A and niacinamide for high-risk skin cancer
This early trial tests whether adding vitamin A and niacinamide (a form of vitamin B3) can help people with a history of certain skin cancers reduce new disease. It is designed for adults with specific prior skin cancer or skin lesion treatment patterns.
Providence, Rhode IslandAges 18 years+ - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT06409819RecruitingPhase 1/Phase 2
Phage therapy for recurrent UTIs in kidney transplant patients
This trial tests a phage (virus that kills bacteria) treatment for women who have had a kidney transplant and keep getting urinary tract infections (UTIs) caused by E. coli bacteria. It aims to see if this therapy can help prevent future infections.
La Jolla, CaliforniaAges 18 years+ - NCT07347769Recruiting
BK virus risk study in kidney transplant patients
This study looks at the type and genetic makeup of BK virus in kidney transplant patients and their donors. It aims to find patients at higher risk for a kidney infection caused by the virus, which could help improve monitoring and treatment.
GrenobleAges 18 years+
Hear when a new Kidney Transplantation Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for kidney transplantation recipients?
- Yes. Clin2 currently lists 150 recruiting kidney transplantation recipients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplantation recipients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplantation recipients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.